Clinical trial
Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza…
NCT00328107 · Protein Sciences Corporation, Industry · Completed
Key facts
| NCT number | NCT00328107 |
|---|---|
| Title | Immunogenicity and Safety of Trivalent Recombinant Hemagglutinin Influenza Vaccine in Healthy Adults |
| Official title | Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. |
| Lead sponsor | Protein Sciences Corporation, Industry |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Influenza |
| Intervention type | Biological |
| Interventions | Influenza Vaccine, recombinant Hemagglutinin |
| Enrollment | 459 |
| Start date | Nov 1, 2004 |
| Primary completion | Aug 1, 2005 |
| Completion | Aug 1, 2005 |
| First posted | May 19, 2006 |
| Last update posted | Jan 12, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: